Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Loh

Showing results (201-210 of 479) with videos related to

Pageof 48
Sort By:
Pediatric Blood & Cancer|May 16, 2015
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)Mignon L Loh, Sarah K Tasian, Karen R Rabin, et al.
Leukemia|September 24, 2004
PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer GroupM L Loh, M G Reynolds, S Vattikuti, et al.
Leukemia|September 27, 2008
Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group studyK Nguyen, M Devidas, S-C Cheng, et al.
Leukemia|June 10, 2018
Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cellsSarah K Tasian, Jessica A Casas, David Posocco, et al.
Haematologica|June 26, 2025
Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group AALL1331 trialLaura E Hogan, Teena Bhatla, Xinxin Xu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 5, 2023
Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemiaSanthosh Kumar Pasupuleti, Karen Chao, Baskar Ramdas, et al.
The Journal of Clinical Endocrinology and Metabolism|August 12, 1999
Effect of testosterone treatment on body composition and muscle strength in men over 65 years of ageP J Snyder, H Peachey, P Hannoush, et al.
Nature|November 4, 2016
Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironmentLei Dong, Wen-Mei Yu, Hong Zheng, et al.
Blood Advances|August 5, 2025
Prognostic Impact of the PredicT-ALL Classifier in the AALL0434 Trial: A Model Combining NGS, MRD and WBC at DiagnosisMathieu Simonin, Nicolas Boissel, Arnaud Petit, et al.
Blood|February 24, 2006
Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01Mignon L Loh, Meredith A Goldwasser, Lewis B Silverman, et al.
Pageof 48

Showing results (201-210 of 479) with videos related to

Sort By:
Pageof 48
Pediatric Blood & Cancer|May 16, 2015
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)Mignon L Loh, Sarah K Tasian, Karen R Rabin, et al.
Leukemia|September 24, 2004
PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer GroupM L Loh, M G Reynolds, S Vattikuti, et al.
Leukemia|September 27, 2008
Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group studyK Nguyen, M Devidas, S-C Cheng, et al.
Leukemia|June 10, 2018
Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cellsSarah K Tasian, Jessica A Casas, David Posocco, et al.
Haematologica|June 26, 2025
Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group AALL1331 trialLaura E Hogan, Teena Bhatla, Xinxin Xu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 5, 2023
Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemiaSanthosh Kumar Pasupuleti, Karen Chao, Baskar Ramdas, et al.
The Journal of Clinical Endocrinology and Metabolism|August 12, 1999
Effect of testosterone treatment on body composition and muscle strength in men over 65 years of ageP J Snyder, H Peachey, P Hannoush, et al.
Nature|November 4, 2016
Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironmentLei Dong, Wen-Mei Yu, Hong Zheng, et al.
Blood Advances|August 5, 2025
Prognostic Impact of the PredicT-ALL Classifier in the AALL0434 Trial: A Model Combining NGS, MRD and WBC at DiagnosisMathieu Simonin, Nicolas Boissel, Arnaud Petit, et al.
Blood|February 24, 2006
Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01Mignon L Loh, Meredith A Goldwasser, Lewis B Silverman, et al.
Pageof 48